Pharmacists encouraged to take leading role in managing minor ailments

A recent event explored ways in which community pharmacy in the UK can take a leading role in managing minor ailments and support the growing trend towards self-care.

Led by Dr Andrew Moore, Director of Pain Research at the Nuffield Department of Anaesthetics at the University of Oxford, the one-day ideas exchange brought together a diverse group of pharmacists, pharmacy technicians, pre-registration pharmacists, pharmacy students and pharmacy practice teachers.

It aimed to provide pharmacists with the tools and information they need to make personalised, evidence-based recommendations for managing aches and pains, and created a forum for all participants to actively identify ways to place community pharmacy at the forefront of pain management.

Medical experts and policymakers agree: self-care can improve both the health of people and certain services within the NHS. This means a greater role for pharmacists.

“Around 57 million GP consultations per year are for minor ailments,” said pharmacist Fin McCaul, an Xchangeathon leader.

“That costs the NHS £2 billion and takes up an hour a day for every GP. But with increasing health literacy and access to technology, consumers are becoming more ‘health smart’ and proactive toward self-care.

“Pharmacists and their (pharmacy) staff should become the recognised experts in managing acute pain and contribute to helping patients manage their own pain.”

Despite the need for increased self-care and the potential for pharmacy staff to play a key part in this self-care journey, a survey of pharmacists and related staff in the UK revealed that nearly a third felt they had insufficient knowledge around different mechanisms of action, doses or contraindications for OTC analgesics – which might hinder their ability to recommend such medicines and/or knowledgeably speak to patients about pain management.

And only around half were very confident when it came to recommending OTC analgesics for back, dental, head.

The Pharmacy Xchangeathon was designed to enable participants to not only understand relevant evidence for OTC pain relief but also to identify practical solutions to support evidence-based decision-making and to equip them to implement best practice when recommending first-line OTC relief.

  1. Andrew Moore kicked off the meeting by discussing why it is crucial for pharmacists to have a thorough understanding of pain.

Antony Chuter, Chair of Pain UK, an alliance of charities representing people in pain, shared patient perspectives of visiting their local pharmacy with minor ailments.

He outlined the simple steps that can be taken to ensure patients have confidence in the pharmacist’s ability to offer support, advice and most importantly, the most appropriate treatment.

Expanding on the theme of self-care, leading pharmacists Fin McCaul and Terry Maguire discussed the evolving landscape, focusing on the NHS and online environment.

The discussions suggested adaptations in order for pharmacies to work in partnership with patients to provide them with the knowledge to manage everyday minor ailments themselves thus easing the pressure on GP services.

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Sanofi & Translate Bio expand collaboration to develop mRNA vaccines

Sanofi Pasteur, the vaccines global business unit of Sanofi, and Translate Bio, a clinical-stage messenger RNA (mRNA) therapeutics company, are expanding their existing 2018...

Sarepta & Codiak to research, develop exosome-based therapeutics

Precision medicine specialist, Sarepta Therapeutics, and Codiak BioSciences, a company at the forefront of advancing engineered exosomes as a new class of biologic medicines,...

Gilead acquires equity interest in pioneering immunotherapy company

Gilead Sciences is acquiring a 49.9% equity interest in Pionyr Immunotherapeutics, a privately held San Fran company developing first-in-class cancer immunotherapies. The acquisition – for...

New class of precision medicine strips cancer of its DNA defences

A new precision medicine targeting cancer’s ability to repair its DNA has shown promising results in the first clinical trial of the drug class. The...

Tonix & Southern Research expand COVID-19 vaccine collaboration to include T cell study

New York biopharma, Tonix Pharmaceuticals, has expanded its strategic collaboration with Southern Research to include a study of T cell immune responses to SARS-CoV-2...

Related news

Avalon GloboCare & BOKU to advance intranasal & oral COVID-19 vaccine candidate

Avalon GloboCare, a New Jersey-based clinical-stage global developer of cell-based technologies and therapeutics, has partnered with the University of Natural Resources and Life Sciences...

Sanofi & Translate Bio expand collaboration to develop mRNA vaccines

Sanofi Pasteur, the vaccines global business unit of Sanofi, and Translate Bio, a clinical-stage messenger RNA (mRNA) therapeutics company, are expanding their existing 2018...

Sarepta & Codiak to research, develop exosome-based therapeutics

Precision medicine specialist, Sarepta Therapeutics, and Codiak BioSciences, a company at the forefront of advancing engineered exosomes as a new class of biologic medicines,...

Gilead acquires equity interest in pioneering immunotherapy company

Gilead Sciences is acquiring a 49.9% equity interest in Pionyr Immunotherapeutics, a privately held San Fran company developing first-in-class cancer immunotherapies. The acquisition – for...